Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition

Authors: Simon, C.1; Stieger, B.2; Kullak-Ublick, G. A.; Fried, M.3; Mueller, S.1; Fritschy, J.-M.4; Wieser, H.G.1; Pauli-Magnus, C.2

Source: Acta Neurologica Scandinavica, Volume 115, Number 4, April 2007 , pp. 232-242(11)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy J-M, Wieser HG, Pauli-Magnus C. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition.

Acta Neurol Scand: DOI:10.1111/j.1600-0404.2006.00761.x.

© 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard. Objectives - 

Interindividual variability in intestinal absorption and bioavailability might contribute to inadequate control of seizures under treatment with carbamazepine and phenytoin. We therefore correlated intestinal expression levels and genetics of CYP3A4, CYP2C9/19, MDR1 and MRP2 with dose requirement and plasma levels of carbamazepine and phenytoin. Materials and methods - 

Epileptic patients on carbamazepine (n = 29) or phenytoin (n = 15) were stratified into a `high'-dose (carbamazepine ≥800 mg/day, phenytoin ≥300 mg/day) and a `low'-dose group (carbamazepine ≤600 mg/day, phenytoin ≤200 mg/day). Duodenal biopsies and DNA were obtained for Western blotting and genotyping studies. Results - 

Low carbamazepine plasma levels showed a trend towards higher intestinal MDR1 expression (P = 0.06). Furthermore, carbamazepine dose was positively correlated with MRP2 expression (P = 0.1). Moreover, MDR1 expression and carbamazepine and phenytoin dose requirement was influenced by the genotype in position 2677 and 3435 of the MDR1 gene. Conclusion - 

Differences in intestinal MDR1 and MRP2 expression may influence carbamazepine and phenytoin disposition and may account for interindividual pharmacokinetic variability.

Keywords: antiepileptic drugs; epilepsy; carbamazepine; phenytoin; intestinal absorption; cytochrome P450; MDR1; MRP2; pharmacokinetics

Document Type: Research article

DOI: 10.1111/j.1600-0404.2006.00761.x

Affiliations: 1: Department of Neurology, University Hospital Zurich, Zurich, Switzerland 2: Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland 3: Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland 4: Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A